|ACADIA Pharmaceuticals Inc.|
11085 Torreyana Road
United States - Map
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinsons disease psychosis, and in Phase II development for Alzheimers disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinsons disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
|ACADIA Pharmaceuticals Inc.’s ISS Governance QuickScore as of Oct 1, 2014 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Uli Hacksell Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Glenn F. Baity ,
VP, Gen. Counsel, Corp. Compliance Officer and Sec.
|Dr. Roger G. Mills M.D.,
Chief Medical Officer and Exec. VP of Devel.
|Mr. Terrence O. Moore ,
Chief Commercial Officer and Exec. VP
|Mr. Stephen R. Davis J.D.,
Chief Financial Officer, Chief Bus. Officer and Exec. VP
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|